The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored
Adults
The usual initial antihypertensive oral dose of Theravask is 5 mg once daily, and the maximum dose is 10 mg once daily.
Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding Theravask to other antihypertensive therapy.
Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently.
Angina
The recommended dose for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect.
Coronary Artery Disease
The recommended dose range for patients with coronary artery disease is 5–10 mg once daily. In clinical studies, the majority of patients required 10 mg.
Children
The effective antihypertensive oral dose in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients.
How supplied
Dosage Forms And Strengths
Tablets
2.5 mg white, diamond, flat-faced, beveled edged, with "Theravask" on one side and "2.5" on the other Tablets: 5 mg white, elongated octagon, flat-faced, beveled edged, with "Theravask" on one side and "5" on the other Tablets: 10 mg white, round, flat-faced, beveled edge, with "Theravask" on one side and "10" on the other
Storage And Handling
2.5 mg Tablets
Theravask – 2.5 mg Tablets (Theravask equivalent to 2.5 mg of Theravask per tablet) are supplied as white, diamond, flat-faced, beveled edged engraved with "Theravask" on one side and "2.5" on the other side and supplied as follows:
NDC 0069-1520-68 Bottle of 90
5 mg Tablets
Theravask – 5 mg Tablets (Theravask equivalent to 5 mg of Theravask per tablet) are white, elongated octagon, flat-faced, beveled edged engraved with both "Theravask" and "5" on one side and plain on the other side and supplied as follows:
NDC 0069-1530-68 Bottle of 90
NDC 0069-1530-41 Unit Dose package of 100
NDC 0069-1530-72 Bottle of 300
10 mg Tablets
Theravask – 10 mg Tablets (Theravask equivalent to 10 mg of Theravask per tablet) are white, round, flat-faced, beveled edged engraved with both "Theravask" and "10" on one side and plain on the other side and supplied as follows:
NDC 0069-1540-68 Bottle of 90
NDC 0069-1540-41 Unit Dose package of 100
Storage
Store bottles at controlled room temperature, 59° to 86°F (15° to 30°C) and dispense in tight, lightresistant containers (USP).
Manufactured by: Pfizer, Pfizer Labs, Division of Pfizer Inc, NY, NY 10017. Revised: March 2015
What other drugs will affect Theravask?
Tell your doctor about all your other medicines, especially:
nitroglycerin;
simvastatin (Zocor, Simcor, Vytorin); or
any other heart or blood pressure medications.
This list is not complete. Other drugs may affect Theravask, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
See also:
Theravask drug interactions (in more detail)
Theravask interactions
Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Theravask, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored
Theravask has been safely administered with thiazide diuretics, α-blockers, β-blockers, ACE inhibitors, long-acting nitrates, sublingual nitroglycerin, nonsteroidal anti-inflammatory drugs, antibiotics and oral hypoglycemic drugs.
In vitro data from studies with human plasma indicate that Theravask has no effect on protein binding of the drugs tested (digoxin, phenytoin, warfarin, or indomethacin).
Simvastatin: Co-administration of multiple doses of 10 mg Theravask with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on Theravask to 20 mg daily.
Grapefruit Juice: Co-administration of 240 mL grapefruit juice with a single oral dose of 10 mg Theravask in 20 healthy volunteers had no significant effect on the pharmacokinetics of Theravask. The study did not allow examination of the effect of genetic polymorphism in CYP3A4, the primary enzyme responsible for metabolism of Theravask; therefore, administration of Theravask with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.
CYP3A4 Inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg Theravask in elderly hypertensive patients (69 to 87 years of age) resulted in a 57% increase in Theravask systemic exposure. Co-administration of erythromycin in healthy volunteers (18 to 43 years of age) did not significantly change Theravask systemic exposure [22% increase in area under the concentration versus time curve (AUC)]. Although the clinical relevance of these findings is uncertain, pharmacokinetic variations may be more pronounced in the elderly.
Strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of Theravask to a greater extent than diltiazem. Theravask should be used with caution when administered with CYP3A4 inhibitors.
Clarithromycin: Clarithromycin is an inhibitor of CYP3A4. There is an increased risk of hypotension in patients receiving clarithromycin with Theravask. Close observation of patients is recommended when Theravask is co-administered with clarithromycin.
CYP3A4 Inducers: There is no data available regarding the effect of CYP3A4 inducers on Theravask. Concomitant use of CYP3A4 inducers (e.g., rifampicin, hypericum perforatum) may decrease the plasma concentrations of Theravask. Theravask should be used with caution when administered with CYP3A4 inducers.
In the following studies, there were no significant changes in the pharmacokinetics of either Theravask or another drug within the study, when co-administered.
Special Studies: Effect of Other Agents on Theravask: Cimetidine: Co-administration of Theravask with cimetidine did not alter the pharmacokinetics of Theravask.
Aluminum/Magnesium (Antacid):Co-administration of aluminum/magnesium (antacid) with a single dose of Theravask had no significant effect on the pharmacokinetics of Theravask.
Sildenafil: A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of Theravask. When Theravask and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.
Effect of Theravask on Other Agents: Atorvastatin: Co-administration of multiple 10 mg doses of Theravask with 80 mg atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
Digoxin: Co-administration of Theravask with digoxin did not change serum digoxin levels or digoxin renal clearance in healthy volunteers.
Ethanol (Alcohol):Single and multiple 10 mg doses of Theravask had no significant effect on the pharmacokinetics of ethanol.
Warfarin: Co-administration of Theravask with warfarin did not change the warfarin prothrombin response time.
Cyclosporin: No drug interaction studies have been conducted with cyclosporin and Theravask in healthy volunteers or other populations, with the exception of renal transplant patients. Various studies in renal transplant patients report that co-administration of Theravask with cyclosporin affects the trough concentrations of cyclosporin, from no change up to an average increase of 40%. Consideration should be given for monitoring cyclosporin levels in renal transplant patients on Theravask.
Tacrolimus: There is a risk of increased tacrolimus blood levels when co-administered with Theravask. In order to avoid toxicity of tacrolimus, administration of Theravask in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.
European Chemicals Agency - ECHA. "3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
PubMed Health. "Norvasc: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Theravask are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Theravask. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported frequency of use
No survey data has been collected yet
Consumer reported doses
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
